Design-driven engineering of robust mammalian sense-and-respond functions: from parts to programs
Project Number5R01EB026510-06
Former Number2R01EB026510-05
Contact PI/Project LeaderLEONARD, JOSHUA NATHANIEL Other PIs
Awardee OrganizationNORTHWESTERN UNIVERSITY
Description
Abstract Text
Project Summary
The overarching goal of this project is to enable the use of engineered cell therapies to safely and effectively
treat conditions ranging across cancer, autoimmune disease, and regenerative medicine. Engineered cell
therapies are an exciting frontier, with early successes in cancer treatment demonstrating the transformative
potential of this approach. Customized cell therapies could yield safe and effective treatments for many
applications beyond cancer, but realizing this potential is limited by the fact that evaluating a potential therapeutic
strategy requires extensive time and resources to implement it. The goal of this project is to flip this paradigm—
to enable spending less time building and thus focus on evaluating potentially useful strategies.
This project will develop state-of-the-art technologies for cell engineering and enable their application to solve
three open, complementary, clinically motivated challenges. The first aim is to develop the technology,
understanding, and computational tools required to build genetic programs that employ natural mechanisms for
implementing long-lived memory. Natural systems employ genetic memory to drive processes such as
differentiation and development by adding and removing stable marks to the genome. Although research has
yielded insights into how to drive such changes, bioengineers do not yet have the ability to leverage those
insights to build programs that implement these effects for useful purposes. This project will address this need
by developing genetic programs that exhibit stable behaviors including inducible and autonomous state
switching. The second aim will generate novel candidate cell therapies for treating cancer that leverage
foundational advances for engineering cells to evaluate and respond to external cues (e.g., unique markers of
the tumor site) to induce desired therapeutic behaviors. This work will develop programs hypothesized to improve
both safety and efficacy of these approaches. A key aspect of this work is employing model-guided design to
evaluate and refine genetic programs to confer desired behaviors. The third aim will develop a computational
framework enabling computer-assisted design of genetic programs. Current design is limited by the imagination
of the designer—a human must propose a design which is subsequently evaluated. This aim will make the
transformative leap to semi-automated design, establishing workflows and tools that are freely accessible to
researchers in a graphics-enabled open software framework.
Public Health Relevance Statement
Project Narrative
Engineered cell therapies represent an exciting frontier in medicine, and fully realizing the promise of this
approach will require technologies and tools that enable bioengineers to efficiently design, build, and evaluate
customized cellular functions that meet specific clinical needs. Towards that goal, this project will develop
synthetic biology technologies and computational design tools for engineering cells to sense, evaluate, and
respond to their environment in useful ways. Such capabilities will facilitate the development of safer and more
effective treatments in areas including cancer, autoimmune disease, and regenerative medicine.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
160079455
UEI
EXZVPWZBLUE8
Project Start Date
01-August-2018
Project End Date
31-March-2027
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$580,634
Direct Costs
$411,289
Indirect Costs
$169,345
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$580,634
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB026510-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB026510-06
Patents
No Patents information available for 5R01EB026510-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB026510-06
Clinical Studies
No Clinical Studies information available for 5R01EB026510-06
News and More
Related News Releases
No news release information available for 5R01EB026510-06
History
No Historical information available for 5R01EB026510-06
Similar Projects
No Similar Projects information available for 5R01EB026510-06